Related Experiment Video
Updated: Jun 24, 2026

Feeding of Ticks on Animals for Transmission and Xenodiagnosis in Lyme Disease Research
Published on: August 31, 2013
Annexin A2 antibodies in post-treatment Lyme disease
John B Miller1, Alison W Rebman2, Marcia Daniela Villegas de Flores2
1Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building Center Tower, Suite 4100, Baltimore, MD 21224, USA.
Background:
Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD).
Objectives:
Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.
Design And Methods:
Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.
Results:
Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden.
Conclusion:
Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.
More Related Videos
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Rocky Mountain Spotted Fever
Encephalitis ll: Pathophysiology

